The rapid expansion of in vivo gene and cell therapies is redefining lentiviral vector (LV) manufacturing requirements. Systemic delivery demands significantly higher vector quantities, consistent quality, and cost-effective scalability, which traditional batch-based HEK293 transient transfection platforms were not designed to deliver. This presentation highlights how continuous, scalable perfusion enables a transformative shift in LV manufacturing tailored for in vivo applications. We demonstrate a robust, scalable platform capable of supporting large-scale (up to 2,000 L) commercial manufacturing for in-vivo gene and cell therapies.

https://go.ncsu.edu/btec_seminar